Bristol Myers Squibb (CELG-RI) Return on Invested Capital (2009 - 2026)

Bristol Myers Squibb has disclosed Return on Invested Capital across 17 years of filings, most recently posting 0.0% for Q1 2026.

• In Q1 2026, Return on Invested Capital changed 0.0% year-over-year to 0.0%; the TTM figure through Mar 2026 stood at 0.0% (changed 0.0% YoY), while the FY2025 annual figure was 0.0%, changed 0.0% from the prior year.
• Return on Invested Capital retreated to 0.0% in Q1 2026, from 0.0% in the prior quarter.
• Over the last five years, Return on Invested Capital for CELG-RI reached as high as 0.0% in Q1 2023 and fell as low as 0.01% in Q1 2024.
• The 5-year median for Return on Invested Capital is 0.0% (2022), against an average of 0.0%.
• Annual changes were most pronounced in 2024 — Return on Invested Capital decreased 1 bps — and 2025, when it rose 1 bps.
• A 5-year view of Return on Invested Capital shows it stood at 0.0% in 2022, then rose by 21 bps to 0.0% in 2023, then tumbled by 903 bps to 0.0% in 2024, then soared by 87 bps to 0.0% in 2025, then retreated by 5 bps to 0.0% in 2026.
• According to Business Quant data, Return on Invested Capital over the past three periods registered 0.0%, 0.0%, and 0.0% for Q1 2026, Q4 2025, and Q3 2025 respectively.